XML 89 R71.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative Agreements (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Nov. 30, 2013
USD ($)
market
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Agreements                          
Revenue recognized     $ 70,571 $ 67,437 $ 62,353 $ 60,525 $ 55,293 $ 48,768 $ 44,130 $ 34,046 $ 260,886 $ 182,237 $ 91,245
Deferred reimbursements     7,406       8,906       7,406 8,906  
Accrued expenses and other current liabilities     96,841       $ 99,901       96,841 $ 99,901  
Collaborative Arrangements                          
Collaborative Agreements                          
Conditional aggregate payments per indication $ 88,000                        
Discovery program fee $ 10,000                        
Term of agreement 5 years                        
Payments for collaborative agreement $ 7,000                        
Collaborative Arrangements | GSK                          
Collaborative Agreements                          
Payments for collaborative agreement                     1,300    
Revised Agreement | GSK                          
Collaborative Agreements                          
Potential milestone payments upon achievement of post-approval and sales-based milestones   $ 40,000                      
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones | market   8                      
Revenue recognized                     21,700    
Deferred reimbursements     8,900               8,900    
Accrued expenses and other current liabilities     $ 6,600               $ 6,600